Abstract: The present invention provides compositions and methods using certain GPR4-regulated genes and expression products thereof (namely YAP1, CTGF, CCND3, BDNF, VCL, ITGB3) for diagnosis, treatment and prevention of Alzheimer's disease and Mild Cognitive Impairment. The present invention also relates to a method of identifying therapeutic agents to treat and diagnose Alzheimer's disease or Mild Cognitive Impairment based on the differential expression of GPR4-regulated genes.

Abstract: The present invention provides compositions and methods using SNCA-mediated genes and expression products thereof for diagnosis, treatment and prevention of Parkinson's disease. The present invention also relates to a method of identifying therapeutic agents to treat and diagnose Parkinson's disease based on SNCA-mediated genes.

Abstract: The present invention provides compositions and methods using APOE4 motif-mediated genes and expression products thereof for diagnosis, treatment and prevention of Alzheimer's disease and mild cognitive impairment. The present invention also relates to a method of identifying therapeutic agents to treat and diagnose Alzheimer's disease or mild cognitive impairment based on APOE4 motif-mediated genes.

Abstract: Disclosed herein are methods of treating or preventing cell death-related sensory cell loss in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject. Also disclosed are methods of treating or preventing drug-induced ototoxicity in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject.

Abstract: Provided are methods and compositions for protecting treating ischemic events in the retina. The methods include administering a MANF family protein (e.g., MANF, CDNF, or fragments thereof) to a subject and performing another treatment to resolve the blockage underlying the ischemic event. The methods also include administering a MANF family protein to extend the therapeutic window for treatment of a retinal artery occlusion.

Abstract: Disclosed herein are methods of treating or preventing cell death-related sensory cell loss in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject. Also disclosed are methods of treating or preventing drug-induced ototoxicity in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject.

Abstract: NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the NGF variant neurotrophins are also provided.

Abstract: The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferable AGY-94806, or salts or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, Huntington's disease, or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects functional recovery.

Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.

Abstract: The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably SA-4503, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.

Abstract: The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by multiple sclerosis. In other methods, the sigma receptor ligands are administered after MS to facilitate functional recovery. The administration of the sigma receptor ligands causes fasted functional recovery.

Abstract: The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably SA-4503, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.

Abstract: The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by multiple sclerosis. In other methods, the sigma receptor ligands are administered after MS to facilitate functional recovery. The administration of the sigma receptor ligands causes faster functional recovery.

Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.

Abstract: NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the NGF variant neurotrophins are also provided.

Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.

Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.

Abstract: NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the NGF variant neurotrophins are also provided.

Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.

Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.